7kdh › Citations

D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction.
<div class='caption-title'>SARS-CoV-2 Spike (S) Protein Ectodomain Platform for Characterizing the Structures, Antigenicity, and Protease Susceptibility of the S Protein and D614G Mutant</div>
<div class='caption-title'>Biophysics, Antigenicity, and Structure of the S-GSAS Ectodomain in Relation to S-GSAS/PP</div>
Gobeil SM, Janowska K, McDowell S, Mansouri K, Parks R, Manne K, Stalls V, Kopp MF, Henderson R, Edwards RJ, Haynes BF, Acharya P
OpenAccess logo Cell Rep 34 108630 (2021)
Related entries: 7kdg, 7kdi, 7kdj, 7kdk, 7kdl, 7ke4, 7ke6, 7ke7, 7ke8, 7ke9, 7kea, 7keb, 7kec

Cited: 192 times
EuropePMC logo PMID: 33417835

Abstract

The severe acute respiratory coronavirus 2 (SARS-CoV-2) spike (S) protein is the target of vaccine design efforts to end the coronavirus disease 2019 (COVID-19) pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic and are now the dominant form worldwide. Here, we explore S conformational changes and the effects of the D614G mutation on a soluble S ectodomain construct. Cryoelectron microscopy (cryo-EM) structures reveal altered receptor binding domain (RBD) disposition; antigenicity and proteolysis experiments reveal structural changes and enhanced furin cleavage efficiency of the G614 variant. Furthermore, furin cleavage alters the up/down ratio of the RBDs in the G614 S ectodomain, demonstrating an allosteric effect on RBD positioning triggered by changes in the SD2 region, which harbors residue 614 and the furin cleavage site. Our results elucidate SARS-CoV-2 S conformational landscape and allostery and have implications for vaccine design.

Reviews - 7kdh mentioned but not cited (1)

  1. Native, engineered and de novo designed ligands targeting the SARS-CoV-2 spike protein. Costa CFS, Barbosa AJM, Dias AMGC, Roque ACA. Biotechnol Adv 59 107986 (2022)

Articles - 7kdh mentioned but not cited (8)

  1. D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction. Gobeil SM, Janowska K, McDowell S, Mansouri K, Parks R, Manne K, Stalls V, Kopp MF, Henderson R, Edwards RJ, Haynes BF, Acharya P. Cell Rep 34 108630 (2021)
  2. Modelling conformational state dynamics and its role on infection for SARS-CoV-2 Spike protein variants. Teruel N, Mailhot O, Najmanovich RJ. PLoS Comput Biol 17 e1009286 (2021)
  3. Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview. Mehra R, Kepp KP. ACS Infect Dis 8 29-58 (2022)
  4. Design of a multi-epitope vaccine against SARS-CoV-2: immunoinformatic and computational methods. Rafi MO, Al-Khafaji K, Sarker MT, Taskin-Tok T, Rana AS, Rahman MS. RSC Adv 12 4288-4310 (2022)
  5. Landscape-Based Mutational Sensitivity Cartography and Network Community Analysis of the SARS-CoV-2 Spike Protein Structures: Quantifying Functional Effects of the Circulating D614G Variant. Verkhivker GM, Agajanian S, Oztas DY, Gupta G. ACS Omega 6 16216-16233 (2021)
  6. Modeling coronavirus spike protein dynamics: implications for immunogenicity and immune escape. Kunkel G, Madani M, White SJ, Verardi PH, Tarakanova A. Biophys J 120 5592-5618 (2021)
  7. Mutagenic Distinction between the Receptor-Binding and Fusion Subunits of the SARS-CoV-2 Spike Glycoprotein and Its Upshot. Penner RC. Vaccines (Basel) 9 1509 (2021)
  8. Structural heterogeneity and precision of implications drawn from cryo-electron microscopy structures: SARS-CoV-2 spike-protein mutations as a test case. Mehra R, Kepp KP. Eur Biophys J 51 555-568 (2022)


Reviews citing this publication (52)

  1. Mechanisms of SARS-CoV-2 entry into cells. Jackson CB, Farzan M, Chen B, Choe H. Nat Rev Mol Cell Biol 23 3-20 (2022)
  2. The biological and clinical significance of emerging SARS-CoV-2 variants. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, Fera D, Shafer RW. Nat Rev Genet 22 757-773 (2021)
  3. SARS-COV-2 Variants: Differences and Potential of Immune Evasion. Hirabara SM, Serdan TDA, Gorjao R, Masi LN, Pithon-Curi TC, Covas DT, Curi R, Durigon EL. Front Cell Infect Microbiol 11 781429 (2021)
  4. Proteolytic activation of SARS-CoV-2 spike protein. Takeda M. Microbiol Immunol 66 15-23 (2022)
  5. SARS-CoV-2 one year on: evidence for ongoing viral adaptation. Peacock TP, Penrice-Randal R, Hiscox JA, Barclay WS. J Gen Virol 102 (2021)
  6. Mutations and Evolution of the SARS-CoV-2 Spike Protein. Magazine N, Zhang T, Wu Y, McGee MC, Veggiani G, Huang W. Viruses 14 640 (2022)
  7. From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants. Papanikolaou V, Chrysovergis A, Ragos V, Tsiambas E, Katsinis S, Manoli A, Papouliakos S, Roukas D, Mastronikolis S, Peschos D, Batistatou A, Kyrodimos E, Mastronikolis N. Gene 814 146134 (2022)
  8. Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. Thye AY, Law JW, Pusparajah P, Letchumanan V, Chan KG, Lee LH. Biomedicines 9 1303 (2021)
  9. SARS-CoV-2 Omicron variant: Immune escape and vaccine development. Ao D, Lan T, He X, Liu J, Chen L, Baptista-Hon DT, Zhang K, Wei X. MedComm (2020) 3 e126 (2022)
  10. Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Sun C, Xie C, Bu GL, Zhong LY, Zeng MS. Signal Transduct Target Ther 7 202 (2022)
  11. Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. Mengist HM, Kombe Kombe AJ, Mekonnen D, Abebaw A, Getachew M, Jin T. Semin Immunol 55 101533 (2021)
  12. Functional importance of the D614G mutation in the SARS-CoV-2 spike protein. Jackson CB, Zhang L, Farzan M, Choe H. Biochem Biophys Res Commun 538 108-115 (2021)
  13. SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies. Almehdi AM, Khoder G, Alchakee AS, Alsayyid AT, Sarg NH, Soliman SSM. Infection 49 855-876 (2021)
  14. D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity. Bhattacharya M, Chatterjee S, Sharma AR, Agoramoorthy G, Chakraborty C. Appl Microbiol Biotechnol 105 9035-9045 (2021)
  15. Expression and characterization of SARS-CoV-2 spike proteins. Schaub JM, Chou CW, Kuo HC, Javanmardi K, Hsieh CL, Goldsmith J, DiVenere AM, Le KC, Wrapp D, Byrne PO, Hjorth CK, Johnson NV, Ludes-Meyers J, Nguyen AW, Wang N, Lavinder JJ, Ippolito GC, Maynard JA, McLellan JS, Finkelstein IJ. Nat Protoc 16 5339-5356 (2021)
  16. Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics. Kudriavtsev AV, Vakhrusheva AV, Novosеletsky VN, Bozdaganyan ME, Shaitan KV, Kirpichnikov MP, Sokolova OS. Viruses 14 1603 (2022)
  17. Evolution of the SARS-CoV-2 genome and emergence of variants of concern. Safari I, Elahi E. Arch Virol 167 293-305 (2022)
  18. Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. Ghimire D, Han Y, Lu M. Viruses 14 1255 (2022)
  19. Swine Enteric Coronavirus: Diverse Pathogen-Host Interactions. Yan Q, Liu X, Sun Y, Zeng W, Li Y, Zhao F, Wu K, Fan S, Zhao M, Chen J, Yi L. Int J Mol Sci 23 3953 (2022)
  20. The virological impacts of SARS-CoV-2 D614G mutation. Wang C, Zheng Y, Niu Z, Jiang X, Sun Q. J Mol Cell Biol 13 712-720 (2021)
  21. Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern. Pondé RAA. Virology 572 44-54 (2022)
  22. Shooting at a Moving Target-Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. Günl F, Mecate-Zambrano A, Rehländer S, Hinse S, Ludwig S, Brunotte L. Vaccines (Basel) 9 1052 (2021)
  23. Proteases and variants: context matters for SARS-CoV-2 entry assays. Stevens CS, Oguntuyo KY, Lee B. Curr Opin Virol 50 49-58 (2021)
  24. The Future of the COVID-19 Pandemic: How Good (or Bad) Can the SARS-CoV2 Spike Protein Get? Nugent MA. Cells 11 855 (2022)
  25. COVID-19 Research: Lessons from Non-Human Primate Models. Albrecht L, Bishop E, Jay B, Lafoux B, Minoves M, Passaes C. Vaccines (Basel) 9 886 (2021)
  26. Cardiovascular protective properties of oxytocin against COVID-19. Wang SC, Wang YF. Life Sci 270 119130 (2021)
  27. Molecular Level Dissection of Critical Spike Mutations in SARS-CoV-2 Variants of Concern (VOCs): A Simplified Review. Joshi N, Tyagi A, Nigam S. ChemistrySelect 6 7981-7998 (2021)
  28. Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic. Li X, Zhang L, Chen S, Ji W, Li C, Ren L. Infect Genet Evol 93 104971 (2021)
  29. Antibody-mediated immunity to SARS-CoV-2 spike. Errico JM, Adams LJ, Fremont DH. Adv Immunol 154 1-69 (2022)
  30. Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics. Gupta Y, Savytskyi OV, Coban M, Venugopal A, Pleqi V, Weber CA, Chitale R, Durvasula R, Hopkins C, Kempaiah P, Caulfield TR. Mol Aspects Med 91 101151 (2023)
  31. COVID-19: Mechanistic Model of the African Paradox Supports the Central Role of the NF-κB Pathway. Kircheis R, Schuster M, Planz O. Viruses 13 1887 (2021)
  32. The origins of COVID-19 pandemic: A brief overview. Hao YJ, Wang YL, Wang MY, Zhou L, Shi JY, Cao JM, Wang DP. Transbound Emerg Dis 69 3181-3197 (2022)
  33. Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations. Cocherie T, Zafilaza K, Leducq V, Marot S, Calvez V, Marcelin AG, Todesco E. Microorganisms 11 30 (2022)
  34. Evolution of the SARS-CoV-2 Omicron spike. Parsons RJ, Acharya P. Cell Rep 42 113444 (2023)
  35. Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. Rayati Damavandi A, Dowran R, Al Sharif S, Kashanchi F, Jafari R. Med Microbiol Immunol 211 79-103 (2022)
  36. S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review. Nejat R, Torshizi MF, Najafi DJ. Vaccines (Basel) 11 204 (2023)
  37. SARS-CoV-2 Virology. Li Y, Li JZ. Infect Dis Clin North Am 36 251-265 (2022)
  38. Mechanism and evolution of human ACE2 binding by SARS-CoV-2 spike. Wrobel AG. Curr Opin Struct Biol 81 102619 (2023)
  39. Novel coronavirus mutations: Vaccine development and challenges. Luo WR, Wu XM, Wang W, Yu JL, Chen QQ, Zhou X, Huang X, Pan HF, Liu ZR, Gao Y, He J. Microb Pathog 173 105828 (2022)
  40. The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition. Qiao S, Zhang S, Ge J, Wang X. FEBS Open Bio 12 1602-1622 (2022)
  41. Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion. Xue S, Han Y, Wu F, Wang Q. Protein Cell 15 403-418 (2024)
  42. Strategies for the Production of Molecular Animations. Werner E. Front Bioinform 2 793914 (2022)
  43. The effects of amino acid substitution of spike protein and genomic recombination on the evolution of SARS-CoV-2. Fang L, Xu J, Zhao Y, Fan J, Shen J, Liu W, Cao G. Front Microbiol 14 1228128 (2023)
  44. Towards Quantum-Chemical Level Calculations of SARS-CoV-2 Spike Protein Variants of Concern by First Principles Density Functional Theory. Ching WY, Adhikari P, Jawad B, Podgornik R. Biomedicines 11 517 (2023)
  45. Molecular and Clinical Investigation of COVID-19: From Pathogenesis and Immune Responses to Novel Diagnosis and Treatment. Kashani NR, Azadbakht J, Ehteram H, Kashani HH, Rajabi-Moghadam H, Ahmad E, Nikzad H, Hosseini ES. Front Mol Biosci 9 770775 (2022)
  46. SARS-CoV-2 Spike-Mediated Entry and Its Regulation by Host Innate Immunity. Yu S, Hu H, Ai Q, Bai R, Ma K, Zhou M, Wang S. Viruses 15 639 (2023)
  47. Mutational dynamics of SARS-CoV-2: Impact on future COVID-19 vaccine strategies. Faraji N, Zeinali T, Joukar F, Aleali MS, Eslami N, Shenagari M, Mansour-Ghanaei F. Heliyon 10 e30208 (2024)
  48. Cryo-electron microscopy in the study of virus entry and infection. Dutta M, Acharya P. Front Mol Biosci 11 1429180 (2024)
  49. Host Cell Proteases Involved in Human Respiratory Viral Infections and Their Inhibitors: A Review. Lubinski B, Whittaker GR. Viruses 16 984 (2024)
  50. Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants. Yajima H, Nomai T, Okumura K, Maenaka K, Genotype to Phenotype Japan (G2P-Japan) Consortium, Ito J, Hashiguchi T, Sato K. mBio 15 e0322023 (2024)
  51. Potential impacts of SARS-CoV-2 on parathyroid: current advances and trends. Murugan AK, Alzahrani AS. Endocrine 81 391-408 (2023)
  52. Significance of Artificial Intelligence in the Study of Virus-Host Cell Interactions. Elste J, Saini A, Mejia-Alvarez R, Mejía A, Millán-Pacheco C, Swanson-Mungerson M, Tiwari V. Biomolecules 14 911 (2024)

Articles citing this publication (131)

  1. Structural impact on SARS-CoV-2 spike protein by D614G substitution. Zhang J, Cai Y, Xiao T, Lu J, Peng H, Sterling SM, Walsh RM, Rits-Volloch S, Zhu H, Woosley AN, Yang W, Sliz P, Chen B. Science 372 525-530 (2021)
  2. Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. Gobeil SM, Janowska K, McDowell S, Mansouri K, Parks R, Stalls V, Kopp MF, Manne K, Li D, Wiehe K, Saunders KO, Edwards RJ, Korber B, Haynes BF, Henderson R, Acharya P. Science 373 eabi6226 (2021)
  3. D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. Weissman D, Alameh MG, de Silva T, Collini P, Hornsby H, Brown R, LaBranche CC, Edwards RJ, Sutherland L, Santra S, Mansouri K, Gobeil S, McDanal C, Pardi N, Hengartner N, Lin PJC, Tam Y, Shaw PA, Lewis MG, Boesler C, Şahin U, Acharya P, Haynes BF, Korber B, Montefiori DC. Cell Host Microbe 29 23-31.e4 (2021)
  4. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH, Mantus G, Nyhoff LE, Adelman MW, Fineman R, Patel S, Byram R, Gomes DN, Michael G, Abdullahi H, Beydoun N, Panganiban B, McNair N, Hellmeister K, Pitts J, Winters J, Kleinhenz J, Usher J, O'Keefe JB, Piantadosi A, Waggoner JJ, Babiker A, Stephens DS, Anderson EJ, Edupuganti S, Rouphael N, Ahmed R, Wrammert J, Suthar MS. Cell Host Microbe 29 516-521.e3 (2021)
  5. Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants. Laffeber C, de Koning K, Kanaar R, Lebbink JHG. J Mol Biol 433 167058 (2021)
  6. The SARS-CoV-2 Spike variant D614G favors an open conformational state. Mansbach RA, Chakraborty S, Nguyen K, Montefiori DC, Korber B, Gnanakaran S. Sci Adv 7 eabf3671 (2021)
  7. Structural diversity of the SARS-CoV-2 Omicron spike. Gobeil SM, Henderson R, Stalls V, Janowska K, Huang X, May A, Speakman M, Beaudoin E, Manne K, Li D, Parks R, Barr M, Deyton M, Martin M, Mansouri K, Edwards RJ, Eaton A, Montefiori DC, Sempowski GD, Saunders KO, Wiehe K, Williams W, Korber B, Haynes BF, Acharya P. Mol Cell 82 2050-2068.e6 (2022)
  8. Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution. Amicone M, Borges V, Alves MJ, Isidro J, Zé-Zé L, Duarte S, Vieira L, Guiomar R, Gomes JP, Gordo I. Evol Med Public Health 10 142-155 (2022)
  9. Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum. Bates TA, Leier HC, Lyski ZL, McBride SK, Coulter FJ, Weinstein JB, Goodman JR, Lu Z, Siegel SAR, Sullivan P, Strnad M, Brunton AE, Lee DX, Adey AC, Bimber BN, O'Roak BJ, Curlin ME, Messer WB, Tafesse FG. Nat Commun 12 5135 (2021)
  10. Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation. Fraser BJ, Beldar S, Seitova A, Hutchinson A, Mannar D, Li Y, Kwon D, Tan R, Wilson RP, Leopold K, Subramaniam S, Halabelian L, Arrowsmith CH, Bénard F. Nat Chem Biol 18 963-971 (2022)
  11. The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways. Laporte M, Raeymaekers V, Van Berwaer R, Vandeput J, Marchand-Casas I, Thibaut HJ, Van Looveren D, Martens K, Hoffmann M, Maes P, Pöhlmann S, Naesens L, Stevaert A. PLoS Pathog 17 e1009500 (2021)
  12. Cryo-EM structure of a SARS-CoV-2 omicron spike protein ectodomain. Ye G, Liu B, Li F. Nat Commun 13 1214 (2022)
  13. Emergence and spread of a SARS-CoV-2 lineage A variant (A.23.1) with altered spike protein in Uganda. Bugembe DL, Phan MVT, Ssewanyana I, Semanda P, Nansumba H, Dhaala B, Nabadda S, O'Toole ÁN, Rambaut A, Kaleebu P, Cotten M. Nat Microbiol 6 1094-1101 (2021)
  14. Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike. Stalls V, Lindenberger J, Gobeil SM, Henderson R, Parks R, Barr M, Deyton M, Martin M, Janowska K, Huang X, May A, Speakman M, Beaudoin E, Kraft B, Lu X, Edwards RJ, Eaton A, Montefiori DC, Williams WB, Saunders KO, Wiehe K, Haynes BF, Acharya P. Cell Rep 39 111009 (2022)
  15. Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion. Baral P, Bhattarai N, Hossen ML, Stebliankin V, Gerstman BS, Narasimhan G, Chapagain PP. Biochem Biophys Res Commun 574 14-19 (2021)
  16. Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2. Chen C, Boorla VS, Banerjee D, Chowdhury R, Cavener VS, Nissly RH, Gontu A, Boyle NR, Vandegrift K, Nair MS, Kuchipudi SV, Maranas CD. Proc Natl Acad Sci U S A 118 e2106480118 (2021)
  17. Distant residues modulate conformational opening in SARS-CoV-2 spike protein. Ray D, Le L, Andricioaei I. Proc Natl Acad Sci U S A 118 e2100943118 (2021)
  18. Molecular insights into receptor binding energetics and neutralization of SARS-CoV-2 variants. Koehler M, Ray A, Moreira RA, Juniku B, Poma AB, Alsteens D. Nat Commun 12 6977 (2021)
  19. SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy. Yang Z, Han Y, Ding S, Shi W, Zhou T, Finzi A, Kwong PD, Mothes W, Lu M. mBio 13 e0322721 (2021)
  20. Genomic Variations in the Structural Proteins of SARS-CoV-2 and Their Deleterious Impact on Pathogenesis: A Comparative Genomics Approach. Mohammad T, Choudhury A, Habib I, Asrani P, Mathur Y, Umair M, Anjum F, Shafie A, Yadav DK, Hassan MI. Front Cell Infect Microbiol 11 765039 (2021)
  21. Dynamic Network Modeling of Allosteric Interactions and Communication Pathways in the SARS-CoV-2 Spike Trimer Mutants: Differential Modulation of Conformational Landscapes and Signal Transmission via Cascades of Regulatory Switches. Verkhivker GM, Di Paola L. J Phys Chem B 125 850-873 (2021)
  22. D614G mutation in the SARS-CoV-2 spike protein enhances viral fitness by desensitizing it to temperature-dependent denaturation. Yang TJ, Yu PY, Chang YC, Hsu SD. J Biol Chem 297 101238 (2021)
  23. Evolution of the SARS-CoV-2 spike protein in the human host. Wrobel AG, Benton DJ, Roustan C, Borg A, Hussain S, Martin SR, Rosenthal PB, Skehel JJ, Gamblin SJ. Nat Commun 13 1178 (2022)
  24. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus. Kim YJ, Jang US, Soh SM, Lee JY, Lee HR. Viruses 13 633 (2021)
  25. Predicting Mutational Effects on Receptor Binding of the Spike Protein of SARS-CoV-2 Variants. Bai C, Wang J, Chen G, Zhang H, An K, Xu P, Du Y, Ye RD, Saha A, Zhang A, Warshel A. J Am Chem Soc 143 17646-17654 (2021)
  26. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease. Kreutzberger AJB, Sanyal A, Ojha R, Pyle JD, Vapalahti O, Balistreri G, Kirchhausen T. J Virol 95 e0097521 (2021)
  27. SARS-CoV-2 spike opening dynamics and energetics reveal the individual roles of glycans and their collective impact. Pang YT, Acharya A, Lynch DL, Pavlova A, Gumbart JC. Commun Biol 5 1170 (2022)
  28. D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer via Enhanced Furin-Mediated Spike Cleavage. Cheng YW, Chao TL, Li CL, Wang SH, Kao HC, Tsai YM, Wang HY, Hsieh CL, Lin YY, Chen PJ, Chang SY, Yeh SH. mBio 12 e0058721 (2021)
  29. Mutations in the B.1.1.7 SARS-CoV-2 Spike Protein Reduce Receptor-Binding Affinity and Induce a Flexible Link to the Fusion Peptide. Socher E, Conrad M, Heger L, Paulsen F, Sticht H, Zunke F, Arnold P. Biomedicines 9 525 (2021)
  30. Letter Profiles of current COVID-19 vaccines. Heinz FX, Stiasny K. Wien Klin Wochenschr 133 271-283 (2021)
  31. SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity. Meng B, Datir R, Choi J, CITIID-NIHR Bioresource COVID-19 Collaboration, Bradley JR, Smith KGC, Lee JH, Gupta RK. Cell Rep 40 111220 (2022)
  32. Enhancing the Prefusion Conformational Stability of SARS-CoV-2 Spike Protein Through Structure-Guided Design. Riley TP, Chou HT, Hu R, Bzymek KP, Correia AR, Partin AC, Li D, Gong D, Wang Z, Yu X, Manzanillo P, Garces F. Front Immunol 12 660198 (2021)
  33. Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy. Gupta Y, Maciorowski D, Zak SE, Kulkarni CV, Herbert AS, Durvasula R, Fareed J, Dye JM, Kempaiah P. Int J Biol Macromol 183 203-212 (2021)
  34. Molecular characterisation and tracking of severe acute respiratory syndrome coronavirus 2 in Thailand, 2020-2022. Puenpa J, Rattanakomol P, Saengdao N, Chansaenroj J, Yorsaeng R, Suwannakarn K, Thanasitthichai S, Vongpunsawad S, Poovorawan Y. Arch Virol 168 26 (2023)
  35. Mutations of SARS-CoV-2 RBD May Alter Its Molecular Structure to Improve Its Infection Efficiency. Alaofi AL, Shahid M. Biomolecules 11 1273 (2021)
  36. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein. Javanmardi K, Segall-Shapiro TH, Chou CW, Boutz DR, Olsen RJ, Xie X, Xia H, Shi PY, Johnson CD, Annapareddy A, Weaver S, Musser JM, Ellington AD, Finkelstein IJ, Gollihar JD. Cell Host Microbe 30 1242-1254.e6 (2022)
  37. Study on SARS-CoV-2 strains in Iran reveals potential contribution of co-infection with and recombination between different strains to the emergence of new strains. Taghizadeh P, Salehi S, Heshmati A, Houshmand SM, InanlooRahatloo K, Mahjoubi F, Sanati MH, Yari H, Alavi A, Jamehdar SA, Dabiri S, Galehdari H, Haghshenas MR, Hashemian AM, Heidarzadeh A, Jahanzad I, Kheyrani E, Piroozmand A, Mojtahedi A, Nikoo HR, Rahimi Bidgoli MM, Rezvani N, Sepehrnejad M, Shakibzadeh A, Shariati G, Seyyedi N, MohammadSaleh Zahraei S, Safari I, Elahi E. Virology 562 63-73 (2021)
  38. Editorial SARS-CoV-2 biology and variants: anticipation of viral evolution and what needs to be done. Luo R, Delaunay-Moisan A, Timmis K, Danchin A. Environ Microbiol 23 2339-2363 (2021)
  39. Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein. Calvaresi V, Wrobel AG, Toporowska J, Hammerschmid D, Doores KJ, Bradshaw RT, Parsons RB, Benton DJ, Roustan C, Reading E, Malim MH, Gamblin SJ, Politis A. Nat Commun 14 1421 (2023)
  40. N-glycosylation profiles of the SARS-CoV-2 spike D614G mutant and its ancestral protein characterized by advanced mass spectrometry. Wang D, Zhou B, Keppel TR, Solano M, Baudys J, Goldstein J, Finn MG, Fan X, Chapman AP, Bundy JL, Woolfitt AR, Osman SH, Pirkle JL, Wentworth DE, Barr JR. Sci Rep 11 23561 (2021)
  41. SARS-CoV-2 evolution influences GBP and IFITM sensitivity. Mesner D, Reuschl AK, Whelan MVX, Bronzovich T, Haider T, Thorne LG, Ragazzini R, Bonfanti P, Towers GJ, Jolly C. Proc Natl Acad Sci U S A 120 e2212577120 (2023)
  42. Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants. Qu P, Evans JP, Kurhade C, Zeng C, Zheng YM, Xu K, Shi PY, Xie X, Liu SL. mBio 14 e0317622 (2023)
  43. Multiple detection and spread of novel strains of the SARS-CoV-2 B.1.177 (B.1.177.75) lineage that test negative by a commercially available nucleocapsid gene real-time RT-PCR. Amato L, Jurisic L, Puglia I, Di Lollo V, Curini V, Torzi G, Di Girolamo A, Mangone I, Mancinelli A, Decaro N, Calistri P, Di Giallonardo F, Lorusso A, D'Alterio N. Emerg Microbes Infect 10 1148-1155 (2021)
  44. RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates. Pan X, Shi J, Hu X, Wu Y, Zeng L, Yao Y, Shang W, Liu K, Gao G, Guo W, Peng Y, Chen S, Gao X, Peng C, Rao J, Zhao J, Gong C, Zhou H, Lu Y, Wang Z, Hu X, Cong W, Fang L, Yan Y, Zhang J, Xiong H, Yi J, Yuan Z, Zhou P, Shan C, Xiao G. Cell Discov 7 82 (2021)
  45. 35B5 antibody potently neutralizes SARS-CoV-2 Omicron by disrupting the N-glycan switch via a conserved spike epitope. Wang X, Chen X, Tan J, Yue S, Zhou R, Xu Y, Lin Y, Yang Y, Zhou Y, Deng K, Chen Z, Ye L, Zhu Y. Cell Host Microbe 30 887-895.e4 (2022)
  46. Early computational detection of potential high-risk SARS-CoV-2 variants. Beguir K, Skwark MJ, Fu Y, Pierrot T, Carranza NL, Laterre A, Kadri I, Korched A, Lowegard AU, Lui BG, Sänger B, Liu Y, Poran A, Muik A, Şahin U. Comput Biol Med 155 106618 (2023)
  47. The Delta SARS-CoV-2 Variant of Concern Induces Distinct Pathogenic Patterns of Respiratory Disease in K18-hACE2 Transgenic Mice Compared to the Ancestral Strain from Wuhan. Liu X, Mostafavi H, Ng WH, Freitas JR, King NJC, Zaid A, Taylor A, Mahalingam S. mBio 13 e0068322 (2022)
  48. The fatty acid site is coupled to functional motifs in the SARS-CoV-2 spike protein and modulates spike allosteric behaviour. Sofia F Oliveira A, Shoemark DK, Avila Ibarra A, Davidson AD, Berger I, Schaffitzel C, Mulholland AJ. Comput Struct Biotechnol J 20 139-147 (2022)
  49. A model for pH coupling of the SARS-CoV-2 spike protein open/closed equilibrium. Warwicker J. Brief Bioinform 22 1499-1507 (2021)
  50. ACE2 N-glycosylation modulates interactions with SARS-CoV-2 spike protein in a site-specific manner. Isobe A, Arai Y, Kuroda D, Okumura N, Ono T, Ushiba S, Nakakita SI, Daidoji T, Suzuki Y, Nakaya T, Matsumoto K, Watanabe Y. Commun Biol 5 1188 (2022)
  51. Genomic characterization unravelling the causative role of SARS-CoV-2 Delta variant of lineage B.1.617.2 in 2nd wave of COVID-19 pandemic in Chhattisgarh, India. Singh P, Sharma K, Singh P, Bhargava A, Negi SS, Sharma P, Bhise M, Tripathi MK, Jindal A, Nagarkar NM. Microb Pathog 164 105404 (2022)
  52. Probing the Allosteric Inhibition Mechanism of a Spike Protein Using Molecular Dynamics Simulations and Active Compound Identifications. Wang Q, Wang L, Zhang Y, Zhang X, Zhang L, Shang W, Bai F. J Med Chem 65 2827-2835 (2022)
  53. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. Kaku Y, Kuwata T, Zahid HM, Hashiguchi T, Noda T, Kuramoto N, Biswas S, Matsumoto K, Shimizu M, Kawanami Y, Shimura K, Onishi C, Muramoto Y, Suzuki T, Sasaki J, Nagasaki Y, Minami R, Motozono C, Toyoda M, Takahashi H, Kishi H, Fujii K, Tatsuke T, Ikeda T, Maeda Y, Ueno T, Koyanagi Y, Iwagoe H, Matsushita S. Cell Rep 36 109385 (2021)
  54. In situ structure and dynamics of an alphacoronavirus spike protein by cryo-ET and cryo-EM. Huang CY, Draczkowski P, Wang YS, Chang CY, Chien YC, Cheng YH, Wu YM, Wang CH, Chang YC, Chang YC, Yang TJ, Tsai YX, Khoo KH, Chang HW, Hsu SD. Nat Commun 13 4877 (2022)
  55. The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutation. Ginex T, Marco-Marín C, Wieczór M, Mata CP, Krieger J, Ruiz-Rodriguez P, López-Redondo ML, Francés-Gómez C, Melero R, Sánchez-Sorzano CÓ, Martínez M, Gougeard N, Forcada-Nadal A, Zamora-Caballero S, Gozalbo-Rovira R, Sanz-Frasquet C, Arranz R, Bravo J, Rubio V, Marina A, IBV-Covid19-Pipeline, Geller R, Comas I, Gil C, Coscolla M, Orozco M, Llácer JL, Carazo JM. PLoS Pathog 18 e1010631 (2022)
  56. A rigorous framework for detecting SARS-CoV-2 spike protein mutational ensemble from genomic and structural features. Fatihi S, Rathore S, Pathak AK, Gahlot D, Mukerji M, Jatana N, Thukral L. Curr Res Struct Biol 3 290-300 (2021)
  57. Cryo-EM structures and binding of mouse and human ACE2 to SARS-CoV-2 variants of concern indicate that mutations enabling immune escape could expand host range. Ni D, Turelli P, Beckert B, Nazarov S, Uchikawa E, Myasnikov A, Pojer F, Trono D, Stahlberg H, Lau K. PLoS Pathog 19 e1011206 (2023)
  58. SARS-CoV-2 integral membrane proteins shape the serological responses of patients with COVID-19. Martin S, Heslan C, Jégou G, Eriksson LA, Le Gallo M, Thibault V, Chevet E, Godey F, Avril T. iScience 24 103185 (2021)
  59. SARS-CoV-2 variant transition dynamics are associated with vaccination rates, number of co-circulating variants, and convalescent immunity. Beesley LJ, Moran KR, Wagh K, Castro LA, Theiler J, Yoon H, Fischer W, Hengartner NW, Korber B, Del Valle SY. EBioMedicine 91 104534 (2023)
  60. Timeline of changes in spike conformational dynamics in emergent SARS-CoV-2 variants reveal progressive stabilization of trimer stalk with altered NTD dynamics. Braet SM, Buckley TSC, Venkatakrishnan V, Dam KA, Bjorkman PJ, Anand GS. Elife 12 e82584 (2023)
  61. A Comprehensive Molecular Epidemiological Analysis of SARS-CoV-2 Infection in Cyprus from April 2020 to January 2021: Evidence of a Highly Polyphyletic and Evolving Epidemic. Chrysostomou AC, Vrancken B, Koumbaris G, Themistokleous G, Aristokleous A, Masia C, Eleftheriou C, Iοannou C, Stylianou DC, Ioannides M, Petrou P, Georgiou V, Hatziyianni A, Lemey P, Vandamme AM, Patsalis PP, Kostrikis LG. Viruses 13 1098 (2021)
  62. Engineered disulfide reveals structural dynamics of locked SARS-CoV-2 spike. Qu K, Chen Q, Ciazynska KA, Liu B, Zhang X, Wang J, He Y, Guan J, He J, Liu T, Zhang X, Carter AP, Xiong X, Briggs JAG. PLoS Pathog 18 e1010583 (2022)
  63. Global variation in SARS-CoV-2 proteome and its implication in pre-lockdown emergence and dissemination of 5 dominant SARS-CoV-2 clades. Patro LPP, Sathyaseelan C, Uttamrao PP, Rathinavelan T. Infect Genet Evol 93 104973 (2021)
  64. Regulation Mechanism for the Binding between the SARS-CoV-2 Spike Protein and Host Angiotensin-Converting Enzyme II. Chen H, Kang Y, Duan M, Hou T. J Phys Chem Lett 12 6252-6261 (2021)
  65. Functional analysis of polymorphisms at the S1/S2 site of SARS-CoV-2 spike protein. Arora P, Sidarovich A, Graichen L, Hörnich B, Hahn A, Hoffmann M, Pöhlmann S. PLoS One 17 e0265453 (2022)
  66. IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern. Chang MR, Tomasovic L, Kuzmina NA, Ronk AJ, Byrne PO, Johnson R, Storm N, Olmedillas E, Hou YJ, Schäfer A, Leist SR, Tse LV, Ke H, Coherd C, Nguyen K, Kamkaew M, Honko A, Zhu Q, Alter G, Saphire EO, McLellan JS, Griffiths A, Baric RS, Bukreyev A, Marasco WA. Nat Commun 13 5814 (2022)
  67. In silico characterization of mutations circulating in SARS-CoV-2 structural proteins. Periwal N, Rathod SB, Pal R, Sharma P, Nebhnani L, Barnwal RP, Arora P, Srivastava KR, Sood V. J Biomol Struct Dyn 40 8216-8231 (2022)
  68. A highly immunogenic live-attenuated vaccine candidate prevents SARS-CoV-2 infection and transmission in hamsters. Li XF, Cui Z, Fan H, Chen Q, Cao L, Qiu HY, Zhang NN, Xu YP, Zhang RR, Zhou C, Ye Q, Deng YQ, Guo Y, Qin S, Fan K, Wang L, Jia Z, Cui Y, Wang X, Qin CF. Innovation (Camb) 3 100221 (2022)
  69. Altered Local Interactions and Long-Range Communications in UK Variant (B.1.1.7) Spike Glycoprotein. Borocci S, Cerchia C, Grottesi A, Sanna N, Prandi IG, Abid N, Beccari AR, Chillemi G, Talarico C. Int J Mol Sci 22 5464 (2021)
  70. Delta Variant with P681R Critical Mutation Revealed by Ultra-Large Atomic-Scale Ab Initio Simulation: Implications for the Fundamentals of Biomolecular Interactions. Adhikari P, Jawad B, Rao P, Podgornik R, Ching WY. Viruses 14 465 (2022)
  71. Genomic Diversity of SARS-CoV-2 in Algeria and North African Countries: What We Know So Far and What We Expect? Menasria T, Aguilera M. Microorganisms 10 467 (2022)
  72. Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach. Kwarteng A, Asiedu E, Sylverken AA, Larbi A, Sakyi SA, Asiedu SO. Infect Genet Evol 91 104815 (2021)
  73. hACE2-Induced Allosteric Activation in SARS-CoV versus SARS-CoV-2 Spike Assemblies Revealed by Structural Dynamics. Chen C, Zhu R, Hodge EA, Díaz-Salinas MA, Nguyen A, Munro JB, Lee KK. ACS Infect Dis 9 1180-1189 (2023)
  74. Capturing a Crucial 'Disorder-to-Order Transition' at the Heart of the Coronavirus Molecular Pathology-Triggered by Highly Persistent, Interchangeable Salt-Bridges. Roy S, Ghosh P, Bandyopadhyay A, Basu S. Vaccines (Basel) 10 301 (2022)
  75. Emergence and Spread of a B.1.1.28-Derived P.6 Lineage with Q675H and Q677H Spike Mutations in Uruguay. Rego N, Salazar C, Paz M, Costábile A, Fajardo A, Ferrés I, Perbolianachis P, Fernández-Calero T, Noya V, Machado MR, Brandes M, Arce R, Arleo M, Possi T, Reyes N, Bentancor MN, Lizasoain A, Bortagaray V, Moller A, Chappos O, Nin N, Hurtado J, Duquía M, González MB, Griffero L, Méndez M, Techera MP, Zanetti J, Pereira E, Rivera B, Maidana M, Alonso M, Smircich P, Arantes I, Mir D, Alonso C, Medina J, Albornoz H, Colina R, Bello G, Moreno P, Moratorio G, Iraola G, Spangenberg L. Viruses 13 1801 (2021)
  76. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination. Graninger M, Camp JV, Aberle SW, Traugott MT, Hoepler W, Puchhammer-Stöckl E, Weseslindtner L, Zoufaly A, Aberle JH, Stiasny K. Front Immunol 13 888794 (2022)
  77. Mutation in a SARS-CoV-2 Haplotype from Sub-Antarctic Chile Reveals New Insights into the Spike's Dynamics. González-Puelma J, Aldridge J, Montes de Oca M, Pinto M, Uribe-Paredes R, Fernández-Goycoolea J, Alvarez-Saravia D, Álvarez H, Encina G, Weitzel T, Muñoz R, Olivera-Nappa Á, Pantano S, Navarrete MA. Viruses 13 883 (2021)
  78. Optimizing variant-specific therapeutic SARS-CoV-2 decoys using deep-learning-guided molecular dynamics simulations. Köchl K, Schopper T, Durmaz V, Parigger L, Singh A, Krassnigg A, Cespugli M, Wu W, Yang X, Zhang Y, Wang WW, Selluski C, Zhao T, Zhang X, Bai C, Lin L, Hu Y, Xie Z, Zhang Z, Yan J, Zatloukal K, Gruber K, Steinkellner G, Gruber CC. Sci Rep 13 774 (2023)
  79. Pre-exascale HPC approaches for molecular dynamics simulations. Covid-19 research: A use case. Wieczór M, Genna V, Aranda J, Badia RM, Gelpí JL, Gapsys V, de Groot BL, Lindahl E, Municoy M, Hospital A, Orozco M. Wiley Interdiscip Rev Comput Mol Sci e1622 (2022)
  80. Progressive membrane-binding mechanism of SARS-CoV-2 variant spike proteins. Overduin M, Kervin TA, Tran A. iScience 25 104722 (2022)
  81. SARS-CoV-2 hijacks neutralizing dimeric IgA for nasal infection and injury in Syrian hamsters1. Zhou B, Zhou R, Chan JF, Zeng J, Zhang Q, Yuan S, Liu L, Robinot R, Shan S, Liu N, Ge J, Kwong HY, Zhou D, Xu H, Chan CC, Poon VK, Chu H, Yue M, Kwan KY, Chan CY, Chan CC, Chik KK, Du Z, Au KK, Huang H, Man HO, Cao J, Li C, Wang Z, Zhou J, Song Y, Yeung ML, To KK, Ho DD, Chakrabarti LA, Wang X, Zhang L, Yuen KY, Chen Z. Emerg Microbes Infect 12 2245921 (2023)
  82. SARS-CoV-2 spike trimer vaccine expressed in Nicotiana benthamiana adjuvanted with Alum elicits protective immune responses in mice. Song SJ, Kim H, Jang EY, Jeon H, Diao HP, Khan MRI, Lee MS, Lee YJ, Nam JH, Kim SR, Kim YJ, Sohn EJ, Hwang I, Choi JH. Plant Biotechnol J 20 2298-2312 (2022)
  83. The ACE2 receptor accelerates but is not biochemically required for SARS-CoV-2 membrane fusion. Cervantes M, Hess T, Morbioli GG, Sengar A, Kasson PM. Chem Sci 14 6997-7004 (2023)
  84. Determination of the denaturation temperature of the Spike protein S1 of SARS-CoV-2 (2019 nCoV) by Raman spectroscopy. Hernández-Arteaga AC, Ojeda-Galván HJ, Rodríguez-Aranda MC, Toro-Vázquez JF, Sánchez J, José-Yacamán M, Navarro-Contreras HR. Spectrochim Acta A Mol Biomol Spectrosc 264 120269 (2022)
  85. Mutation-Induced Long-Range Allosteric Interactions in the Spike Protein Determine the Infectivity of SARS-CoV-2 Emerging Variants. Das JK, Thakuri B, MohanKumar K, Roy S, Sljoka A, Sun GQ, Chakraborty A. ACS Omega 6 31312-31327 (2021)
  86. Network analysis uncovers the communication structure of SARS-CoV-2 spike protein identifying sites for immunogen design. Manrique PD, Chakraborty S, Henderson R, Edwards RJ, Mansbach R, Nguyen K, Stalls V, Saunders C, Mansouri K, Acharya P, Korber B, Gnanakaran S. iScience 26 105855 (2023)
  87. RG203KR Mutations in SARS-CoV-2 Nucleocapsid: Assessing the Impact Using a Virus-Like Particle Model System. Raheja H, Das S, Banerjee A, P D, C D, Mukhopadhyay D, Ramachandra SG, Das S. Microbiol Spectr 10 e0078122 (2022)
  88. Structural effects of spike protein D614G mutation in SARS-CoV-2. Dokainish HM, Sugita Y. Biophys J 122 2910-2920 (2023)
  89. Conformational Variability Correlation Prediction of Transmissibility and Neutralization Escape Ability for Multiple Mutation SARS-CoV-2 Strains using SSSCPreds. Izumi H, Nafie LA, Dukor RK. ACS Omega 6 19323-19329 (2021)
  90. Multifaceted membrane binding head of the SARS-CoV-2 spike protein. Tran A, Kervin TA, Overduin M. Curr Res Struct Biol 4 146-157 (2022)
  91. Quantum Chemical Computation of Omicron Mutations Near Cleavage Sites of the Spike Protein. Adhikari P, Jawad B, Podgornik R, Ching WY. Microorganisms 10 1999 (2022)
  92. SARS-CoV-2 Genomes From Oklahoma, United States. Narayanan S, Ritchey JC, Patil G, Narasaraju T, More S, Malayer J, Saliki J, Kaul A, Agarwal PK, Ramachandran A. Front Genet 11 612571 (2020)
  93. SARS-CoV-2 Spike Protein Downregulates Cell Surface α7nAChR through a Helical Motif in the Spike Neck. Tillman TS, Chen Q, Bondarenko V, Coleman JA, Xu Y, Tang P. ACS Chem Neurosci 14 689-698 (2023)
  94. Structural insights into the effect of mutations in the spike protein of SARS-CoV-2 on the binding with human furin protein. Suleman M, Luqman M, Wei DQ, Ali S, Ali SS, Khan A, Khan H, Ali Z, Khan W, Rizwan M, Ullah N. Heliyon 9 e15083 (2023)
  95. Detection of the Omicron SARS-CoV-2 Lineage and Its BA.1 Variant with Multiplex RT-qPCR. Yolshin ND, Komissarov AB, Varchenko KV, Musaeva TD, Fadeev AV, Lioznov DA. Int J Mol Sci 23 16153 (2022)
  96. Exploring Conformational Landscapes and Cryptic Binding Pockets in Distinct Functional States of the SARS-CoV-2 Omicron BA.1 and BA.2 Trimers: Mutation-Induced Modulation of Protein Dynamics and Network-Guided Prediction of Variant-Specific Allosteric Binding Sites. Verkhivker G, Alshahrani M, Gupta G. Viruses 15 2009 (2023)
  97. Genomic Epidemiology of the SARS-CoV-2 Epidemic in Cyprus from November 2020 to October 2021: The Passage of Waves of Alpha and Delta Variants of Concern. Chrysostomou AC, Vrancken B, Haralambous C, Alexandrou M, Aristokleous A, Christodoulou C, Gregoriou I, Ioannides M, Kalakouta O, Karagiannis C, Koumbaris G, Loizides C, Mendris M, Papastergiou P, Patsalis PC, Pieridou D, Richter J, Schmitt M, Shammas C, Stylianou DC, Themistokleous G, The Comessar Network, Lemey P, Kostrikis LG. Viruses 15 108 (2022)
  98. Ionization of D571 Is Coupled with SARS-CoV-2 Spike Up/Down Equilibrium Revealing the pH-Dependent Allosteric Mechanism of Receptor-Binding Domains. Li T, Yu L, Sun J, Liu J, He X. J Phys Chem B 126 4828-4839 (2022)
  99. SARS-CoV-2 spike variants differ in their allosteric responses to linoleic acid. Oliveira ASF, Shoemark DK, Davidson AD, Berger I, Schaffitzel C, Mulholland AJ. J Mol Cell Biol 15 mjad021 (2023)
  100. Scipion-EM-ProDy: A Graphical Interface for the ProDy Python Package within the Scipion Workflow Engine Enabling Integration of Databases, Simulations and Cryo-Electron Microscopy Image Processing. Krieger JM, Sorzano COS, Carazo JM. Int J Mol Sci 24 14245 (2023)
  101. The Delta variant wave in Tunisia: Genetic diversity, spatio-temporal distribution and evidence of the spread of a divergent AY.122 sub-lineage. Haddad-Boubaker S, Arbi M, Souiai O, Chouikha A, Fares W, Edington K, Sims S, Camma C, Lorusso A, Diagne MM, Diallo A, Boubaker IBB, Ferjani S, Mastouri M, Mhalla S, Karray H, Gargouri S, Bahri O, Trabelsi A, Kallala O, Hannachi N, Chaabouni Y, Smaoui H, Meftah K, Bouhalila SB, Foughali S, Zribi M, Lamari A, Touzi H, Safer M, Alaya NB, Kahla AB, Gdoura M, Triki H. Front Public Health 10 990832 (2022)
  102. Conformational Flexibility and Local Frustration in the Functional States of the SARS-CoV-2 Spike B.1.1.7 and B.1.351 Variants: Mutation-Induced Allosteric Modulation Mechanism of Functional Dynamics and Protein Stability. Verkhivker G. Int J Mol Sci 23 1646 (2022)
  103. Research Support, Non-U.S. Gov't Cooperative and structural relationships of the trimeric Spike with infectivity and antibody escape of the strains Delta (B.1.617.2) and Omicron (BA.2, BA.5, and BQ.1). de Souza AS, de Souza RF, Guzzo CR. J Comput Aided Mol Des 37 585-606 (2023)
  104. Detection of Circulating SARS-CoV-2 Variants of Concern (VOCs) Using a Multiallelic Spectral Genotyping Assay. Chrysostomou AC, Aristokleous A, Rodosthenous JH, Christodoulou C, Stathi G, Kostrikis LG. Life (Basel) 13 304 (2023)
  105. Energetic and structural basis for the differences in infectivity between the wild-type and mutant spike proteins of SARS-CoV-2 in the Mexican population. Bello M, Hasan MK, Hussain N. J Mol Graph Model 107 107970 (2021)
  106. In Silico Approach for the Evaluation of the Potential Antiviral Activity of Extra Virgin Olive Oil (EVOO) Bioactive Constituents Oleuropein and Oleocanthal on Spike Therapeutic Drug Target of SARS-CoV-2. Geromichalou EG, Geromichalos GD. Molecules 27 7572 (2022)
  107. Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy. Chiang CY, Chen MY, Hsu CW, Liu CY, Tsai YW, Liao HC, Yan JY, Chuang ZS, Wang HI, Pan CH, Yu CY, Yu GY, Liao CL, Liu SJ, Chen HW. J Biomed Sci 29 37 (2022)
  108. Molecular Characterization and Cluster Analysis of SARS-CoV-2 Viral Isolates in Kahramanmaraş City, Turkey: The Delta VOC Wave within One Month. Marascio N, Cilburunoglu M, Torun EG, Centofanti F, Mataj E, Equestre M, Bruni R, Quirino A, Matera G, Ciccaglione AR, Yalcinkaya KT. Viruses 15 802 (2023)
  109. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor. Lata S, Akif M. J Cell Biochem 123 1207-1221 (2022)
  110. Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection with the Delta Variant. Cianfarini C, Hassler L, Wysocki J, Hassan A, Nicolaescu V, Elli D, Gula H, Ibrahim AM, Randall G, Henkin J, Batlle D. Cells 13 203 (2024)
  111. Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants. Li Y, Shen Y, Zhang Y, Yan R. Viruses 15 1398 (2023)
  112. The "LLQY" Motif on SARS-CoV-2 Spike Protein Affects S Incorporation into Virus Particles. Du S, Xu W, Wang Y, Li L, Hao P, Tian M, Wang M, Li T, Wu S, Liu Q, Bai J, Qu X, Jin N, Zhou B, Liao M, Li C. J Virol 96 e0189721 (2022)
  113. The emergence of Omicron VOC and its rapid spread and persistence in the Western Amazon. Sgorlon G, Roca TP, Passos-Silva AM, Queiroz JAS, Teixeira KS, Araújo A, Batista FS, Souza VR, Oliveira FM, Morello LG, Marchini FK, Salcedo JMV, Rampazzo RCP, Naveca FG, Vieira D. PLoS One 18 e0285742 (2023)
  114. Transient transfection and purification of SARS-CoV-2 spike protein from mammalian cells. Stalls V, Janowska K, Acharya P. STAR Protoc 3 101603 (2022)
  115. Unraveling the Dynamics of Omicron (BA.1, BA.2, and BA.5) Waves and Emergence of the Deltacton Variant: Genomic Epidemiology of the SARS-CoV-2 Epidemic in Cyprus (Oct 2021-Oct 2022). Chrysostomou AC, Vrancken B, Haralambous C, Alexandrou M, Gregoriou I, Ioannides M, Ioannou C, Kalakouta O, Karagiannis C, Marcou M, Masia C, Mendris M, Papastergiou P, Patsalis PC, Pieridou D, Shammas C, Stylianou DC, Zinieri B, Lemey P, The Comessar Network, Kostrikis LG. Viruses 15 1933 (2023)
  116. An Electrostatically-steered Conformational Selection Mechanism Promotes SARS-CoV-2 Spike Protein Variation. Sorokina M, Belapure J, Tüting C, Paschke R, Papasotiriou I, Rodrigues JPGLM, Kastritis PL. J Mol Biol 434 167637 (2022)
  117. Characterization of monoclonal antibodies against porcine epidemic diarrhea virus S1/S2 junction protein. Huang N, Lang Q, Li L, Ge L, Yang X. AMB Express 13 74 (2023)
  118. Free Energy Simulations of Receptor-Binding Domain Opening of the SARS-CoV-2 Spike Indicate a Barrierless Transition with Slow Conformational Motions. Ovchinnikov V, Karplus M. J Phys Chem B 127 8565-8575 (2023)
  119. Impact of E484Q and L452R Mutations on Structure and Binding Behavior of SARS-CoV-2 B.1.617.1 Using Deep Learning AlphaFold2, Molecular Docking and Dynamics Simulation. Jiao Y, Xing Y, Sun Y. Int J Mol Sci 24 11564 (2023)
  120. Influence of variant-specific mutations, temperature and pH on conformations of a large set of SARS-CoV-2 spike trimer vaccine antigen candidates. Stuible M, Schrag JD, Sheff J, Zoubchenok D, Lord-Dufour S, Cass B, L'Abbé D, Pelletier A, Rossotti MA, Tanha J, Gervais C, Maurice R, El Bakkouri M, Acchione M, Durocher Y. Sci Rep 13 16498 (2023)
  121. Mechanistic study of the transmission pattern of the SARS-CoV-2 omicron variant. An K, Yang X, Luo M, Yan J, Xu P, Zhang H, Li Y, Wu S, Warshel A, Bai C. Proteins 92 705-719 (2024)
  122. Letter Recombinant human interferon-α1b inhibits SARS-CoV-2 better than interferon-α2b in vitro. Shi D, Chen K, Lu X, Cheng L, Weng T, Liu F, Wu N, Li L, Yao H. Virol Sin 37 295-298 (2022)
  123. SARS-CoV-2 Omicron XBB lineage spike structures, conformations, antigenicity, and receptor recognition. Zhang QE, Lindenberger J, Parsons RJ, Thakur B, Parks R, Park CS, Huang X, Sammour S, Janowska K, Spence TN, Edwards RJ, Martin M, Williams WB, Gobeil S, Montefiori DC, Korber B, Saunders KO, Haynes BF, Henderson R, Acharya P. Mol Cell 84 2747-2764.e7 (2024)
  124. Some mechanistic underpinnings of molecular adaptations of SARS-COV-2 spike protein by integrating candidate adaptive polymorphisms with protein dynamics. Ose NJ, Campitelli P, Modi T, Kazan IC, Kumar S, Ozkan SB. Elife 12 RP92063 (2024)
  125. CD81 fusion alters SARS-CoV-2 Spike trafficking. Cone AS, Zhou Y, McNamara RP, Eason AB, Arias GF, Landis JT, Shifflett KW, Chambers MG, Yuan R, Willcox S, Griffith JD, Dittmer DP. mBio 15 e0192224 (2024)
  126. Dynamic expedition of leading mutations in SARS-CoV-2 spike glycoproteins. Hasan M, He Z, Jia M, Leung ACF, Natarajan K, Xu W, Yap S, Zhou F, Chen S, Su H, Zhu K, Su H. Comput Struct Biotechnol J 23 2407-2417 (2024)
  127. Mutational analysis of the spike protein of SARS-COV-2 isolates revealed atomistic features responsible for higher binding and infectivity. Hanifa M, Salman M, Fatima M, Mukhtar N, Almajhdi FN, Zaman N, Suleman M, Ali SS, Waheed Y, Khan A. Front Cell Dev Biol 10 940863 (2022)
  128. Novel neutralizing chicken IgY antibodies targeting 17 potent conserved peptides identified by SARS-CoV-2 proteome microarray, and future prospects. Li J, Liang T, Hei A, Wang X, Li H, Yu X, Zhao R, Gao P, Fang C, Zhou J, Li M, He E, Skog S. Front Immunol 13 1074077 (2022)
  129. Single-Molecule Investigation of the Binding Interface Stability of SARS-CoV-2 Variants with ACE2. Ray A, Minh Tran TT, Santos Natividade RD, Moreira RA, Simpson JD, Mohammed D, Koehler M, L Petitjean SJ, Zhang Q, Bureau F, Gillet L, Poma AB, Alsteens D. ACS Nanosci Au 4 136-145 (2024)
  130. The SARS-CoV-2 Delta (B.1.617.2) variant with spike N501Y mutation in the shadow of Omicron emergence. Salimović-Bešić I, Dedeić-Ljubović A, Zahirović E, Hasanović M, Šehić M, Vukovikj M, Boshevska G, Vegar-Zubović S, Mehmedika-Suljić E, Izetbegović S. Heliyon 8 e12650 (2022)
  131. Vero cell-adapted SARS-CoV-2 strain shows increased viral growth through furin-mediated efficient spike cleavage. Minami S, Kotaki T, Sakai Y, Okamura S, Torii S, Ono C, Motooka D, Hamajima R, Nouda R, Nurdin JA, Yamasaki M, Kanai Y, Ebina H, Maeda Y, Okamoto T, Tachibana T, Matsuura Y, Kobayashi T. Microbiol Spectr 12 e0285923 (2024)


Related citations provided by authors (1)

  1. D614G mutation alters SARS-CoV-2 spike conformational dynamics and protease cleavage susceptibility at the S1/S2 junction.. Gobeil S, Janowska K, McDowell S, Mansouri K, Parks R, Manne K, Stalls V, Kopp M, Henderson R, Edwards RJ, Haynes BF, Acharya P bioRxiv (2020)

Quick links